Metadoxine

Metadoxine blocks adipocyte differentiation in association with inhibition of the protein kinase A-cAMP response element binding protein (PKA-CREB) pathway.

Simultaneous Metadoxine treatment notably inhibits adipogenic differentiation in a dose-dependent manner. Metadoxine treatment from day 4 through day 8 is required for inhibition of MDI-induced preadipocyte differentiation[1]. Metadoxine prevents glutathione depletion and the increase in lipid peroxidation damage caused by ethanol and acetaldehyde in HepG2 cells. In hepatic stellate cells, Metadoxine prevents the increase in collagen and attenuated TNF-α secretion caused by acetaldehyde. Thus, Metadoxine could be useful in preventing the damage produced in early stages of alcoholic liver disease as it prevents the redox imbalance of the hepatocytes and prevents TNF-α induction, one of the earliest events in hepatic damage[2].

[1]. Yang YM, et al. Metadoxine, an ion-pair of pyridoxine and L-2-pyrrolidone-5-carboxylate, blocks adipocyte differentiation in association with inhibition of the PKA-CREB pathway. Arch Biochem Biophys. 2009 Aug 15;488(2):91-9.